DMRA
Price
$20.67
Change
+$0.44 (+2.17%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.28B
28 days until earnings call
Intraday BUY SELL Signals
XBIO
Price
$2.20
Change
-$0.04 (-1.79%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
5.46M
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMRA vs XBIO

DMRA vs XBIO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMRA vs. XBIO commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a Hold and XBIO is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DMRA vs XBIO: Fundamental Ratings
DMRA
XBIO
OUTLOOK RATING
1..100
5890
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3688
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (12) in the Biotechnology industry is in the same range as DMRA (30) in the null industry. This means that XBIO’s stock grew similarly to DMRA’s over the last 12 months.

DMRA's Profit vs Risk Rating (47) in the null industry is somewhat better than the same rating for XBIO (100) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than XBIO’s over the last 12 months.

XBIO's SMR Rating (98) in the Biotechnology industry is in the same range as DMRA (99) in the null industry. This means that XBIO’s stock grew similarly to DMRA’s over the last 12 months.

DMRA's Price Growth Rating (36) in the null industry is somewhat better than the same rating for XBIO (88) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than XBIO’s over the last 12 months.

DMRA's P/E Growth Rating (100) in the null industry is in the same range as XBIO (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMRAXBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (DMRA: $20.23 vs. XBIO: $2.24)
Brand notoriety: DMRA and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMRA: 55% vs. XBIO: 21%
Market capitalization -- DMRA: $1.28B vs. XBIO: $5.46M
DMRA [@Biotechnology] is valued at $1.28B. XBIO’s [@Biotechnology] market capitalization is $5.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMRA’s FA Score shows that 1 FA rating(s) are green while XBIO’s FA Score has 1 green FA rating(s).

  • DMRA’s FA Score: 1 green, 4 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, DMRA is a better buy in the long-term than XBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMRA’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 5 bullish TA indicator(s).

  • DMRA’s TA Score: 4 bullish, 5 bearish.
  • XBIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, XBIO is a better buy in the short-term than DMRA.

Price Growth

DMRA (@Biotechnology) experienced а -0.20% price change this week, while XBIO (@Biotechnology) price change was -9.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.98%. For the same industry, the average monthly price growth was -14.69%, and the average quarterly price growth was -2.11%.

Reported Earning Dates

DMRA is expected to report earnings on Oct 30, 2026.

XBIO is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Biotechnology (-3.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMRA
Daily Signal:
Gain/Loss:
XBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APYX2.500.05
+2.04%
Apyx Medical Corp
RGC6.330.11
+1.77%
Regencell Bioscience Holdings Limited
BRO61.770.87
+1.43%
Brown & Brown
BWMX16.40-0.21
-1.26%
Betterware de Mexico SAPI de CV
AIDX0.41-0.03
-6.32%
20/20 Biolabs Inc

DMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMRA has been loosely correlated with COGT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DMRA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMRA
1D Price
Change %
DMRA100%
-4.93%
COGT - DMRA
49%
Loosely correlated
-1.34%
NERV - DMRA
45%
Loosely correlated
-3.58%
INBX - DMRA
44%
Loosely correlated
-2.15%
RANI - DMRA
44%
Loosely correlated
+0.57%
GNTA - DMRA
38%
Loosely correlated
+14.80%
More

XBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with ELOX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then ELOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-3.45%
ELOX - XBIO
59%
Loosely correlated
+2.61%
NERV - XBIO
33%
Loosely correlated
-3.58%
ACXP - XBIO
33%
Poorly correlated
N/A
TCRT - XBIO
32%
Poorly correlated
+2.59%
DMRA - XBIO
30%
Poorly correlated
-4.93%
More